Disease Domain | Count |
---|---|
Nervous System Diseases | 3 |
Endocrinology and Metabolic Disease | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 3 |
Chemical drugs | 1 |
Unknown | 1 |
Mechanism 5-HT2A receptor antagonists [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date20 Dec 2019 |
Target |
Mechanism PDE1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Mechanism 5-HT2A receptor antagonists [+2] |
Active Org. |
Originator Org. |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Apr 2024 |
Sponsor / Collaborator |
Start Date01 Mar 2024 |
Sponsor / Collaborator |
Start Date01 Mar 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Lumateperone Tosylate ( 5-HT2A receptor x D2 receptor ) | Schizophrenia More | Approved |
ITI-214 ( PDE1 ) | Heart Failure More | Phase 2 |
ITI-333 ( 5-HT2A receptor x D1 receptor x μ opioid receptor ) | Substance-Related Disorders More | Phase 1 |
ITI-1284 ( 5-HT2A receptor x D1 receptor x D2 receptor ) | Depressive Disorder More | Phase 1 |
ITI-1549 ( 5-HT2A receptor ) | Neuropsychiatric syndrome More | Preclinical |